Bay­er buys Eu­ro­pean rights to Bridge­Bio's AT­TR-CM pill

As Bay­er un­der­goes a ma­jor strat­e­gy re­think, with a full-year 2023 up­date slat­ed for Tues­day, the con­glom­er­ate is en­list­ing ex­ter­nal help to boost its car­dio prospects.

The Ger­many-based drug gi­ant is nab­bing the ex­clu­sive li­cense to com­mer­cial­ize Bridge­Bio’s transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) treat­ment can­di­date aco­ramidis in Eu­rope, the com­pa­nies said Mon­day morn­ing.

In ex­change for $310 mil­lion in up­front and near-term mile­stone pay­ments, Bay­er will get its hands on the oral treat­ment can­di­date. “A com­po­nent of the mile­stone pay­ment will be con­tin­gent up­on reg­u­la­to­ry suc­cess,” Ananth Srid­har, SVP of cor­po­rate de­vel­op­ment for Bridge­Bio Car­diore­nal, said in an emailed state­ment to End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER